Administration of A2AR agonists to obese mice caused improvements in glucose homeostasis and adipose tissue inflammation, suggesting that this may show promise for therapeutic treatment of obesity (DeOliveira et al., 2017). The gene discussed is ADORA2A; the disease is obesity due to melanocortin 4 receptor deficiency.